XML 43 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2016
Mar. 31, 2017
Dec. 31, 2016
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2014
Dec. 31, 2012
Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]                
Liability related to unused development funding   $ 6,607,000 $ 11,192,000   $ 11,192,000      
Maximum                
Deferred Revenue Arrangement [Line Items]                
Additional revenue recognized   100,000,000            
Astra Zeneca                
Deferred Revenue Arrangement [Line Items]                
Collaboration Revenue           $ 5,400,000   $ 3,000,000
Payments received for development work           $ 8,000,000 $ 6,000,000 $ 3,000,000
Additional collaboration revenue         800,000      
Milestone payments earned $ 7,200,000              
Unused development funding advanced by AstraZeneca $ 7,400,000              
Milestone revenue recognition     7,200,000 $ 70,000        
Unused development funding paid   200,000            
Liability related to unused development funding   0            
Deferred revenue   $ 0 $ 0   $ 0